Current Edition

Regional News

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But do...
Continue Reading →

Tecentriq extends streak with win in breast cancer trial

Roche's checkpoint inhibitor Tecentriq helped extend progression-free survival in a Phase 3 study of patients with a hard-to-treat form of metastatic breast cancer...
Continue Reading →